Eli Lilly’s sudden decision to shut the door on PBS listing for tirzepatide highlights how Australia is ‘lagging behind’ in funding new medicines.
Eli Lilly’s sudden decision to shut the door on PBS listing for tirzepatide highlights how Australia is ‘lagging behind’ in funding new medicines.
This content is for paid subscribers only.
Start your free trial nowor purchase a monthly or annual subscription to read.